Vafidemstat (ORY-2001)
Multiple Sclerosis, Alzheimer's aggression
Phase 2bPreviously active
Key Facts
Indication
Multiple Sclerosis, Alzheimer's aggression
Phase
Phase 2b
Status
Previously active
Company
About Oryzon Genomics
Oryzon Genomics leverages its proprietary epigenetic platform to discover and develop personalized therapeutics for oncology and CNS diseases. As a publicly traded company, it has advanced its lead LSD1 inhibitor, iadademstat, into multiple Phase II trials, including for acute myeloid leukemia (AML) and essential thrombocythemia, while also expanding its patent portfolio globally. The company's strategy focuses on biomarker-driven development and combination therapies, particularly with immuno-oncology agents, to address significant unmet medical needs.
View full company profile